Comparing Aclarion (NASDAQ:ACON) and OneMedNet (NASDAQ:ONMDW)

OneMedNet (NASDAQ:ONMDW) and Aclarion (NASDAQ:ACON) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, earnings and valuation.

Valuation and Earnings

This table compares OneMedNet and Aclarion”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OneMedNet	$1.46 million	N/A	N/A	N/A	N/A
Aclarion	$80,000.00	95.62	-$7.23 million	($7.40)	-0.36

OneMedNet has higher revenue and earnings than Aclarion.

Analyst Recommendations

This is a summary of recent ratings for OneMedNet and Aclarion, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OneMedNet	0	0	0	0	0.00
Aclarion	1	0	1	0	2.00

Aclarion has a consensus target price of $7.50, suggesting a potential upside of 182.38%. Given Aclarion’s stronger consensus rating and higher possible upside, analysts clearly believe Aclarion is more favorable than OneMedNet.

Insider & Institutional Ownership

7.5% of Aclarion shares are owned by institutional investors. 0.0% of Aclarion shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares OneMedNet and Aclarion’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
OneMedNet	N/A	N/A	N/A
Aclarion	-10,948.81%	-59.34%	-56.12%

Summary

Aclarion beats OneMedNet on 5 of the 9 factors compared between the two stocks.

About OneMedNet

OneMedNet Corporation provides clinical imaging solutions. It offers iRWD, a solution that utilizes AI to securely de-identify, search, and curate imaging data for its partner network consisting of medical and academic research institutions to generate progression in stages of medical research, discovery and diagnostics that span the field of life sciences. The company is based in Eden Prairie, Minnesota.

About Aclarion

Aclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.